TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR CM)
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR CM) explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR CM) trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR CM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to cut heart deaths in rare heart condition
Disease control Recruiting nowThis study tests a new medicine, NNC6019-0001, to see if it can lower the risk of heart-related death and hospital stays in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart. About 1,280 adults with ATTR-CM will …
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR CM)
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug for stiff heart disease gets Real-World check in 2,000 patients
Knowledge-focused Recruiting nowThis study watches how a new medication, acoramidis, works in daily life for people with a serious heart condition called ATTR-CM. Researchers will track up to 2,000 adults in Europe to see how the drug is used, how safe it is, and how it affects heart function and quality of lif…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR CM)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 22, 2026 14:03 UTC